TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma
暂无分享，去创建一个
O. Chinot | K. Mokhtari | A. D. Di Stefano | D. Branger | A. Picca | Y. Schmitt | P. Augereau | D. Meyronet | Nabila Rousseaux | E. Le Rhun | Franck Bielle | A. Iavarone | Elisabeth Cohen-Jonathan Moyal | Marc Sanson | Quentin Letourneur | F. Ducray | J. Savatovsky | Ariane Murielle Mbekwe Yepnang | Candice Estellat | Frédérique Charbonneau | Christine Fardeau